Groups
Company Size (Fulltime employees)
Looking for
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Feier Chen United States

As China Focus conference organizer, MyBioGate is a premier cross-border healthcare consulting firm serving Biotech and Medtech clients, and the Chinese Pharma companies and investors. We offer marketing, strategy and execution support to help healthcare innovation to grow by taking advantage of China’s huge market potential. We help innovative companies with China-Landing services, and help them find reliable Chinese investors and partners. MyBioGate is committed to linking healthcare innovations in China and overseas. We share global healthcare innovation, entrepreneurship, investment trends, KOL opinions, important events and conferences, in-depth research and analysis, allowing Chinese medical and health companies and investors to gain insight into trends and seize investment opportunities. Our China Focus forums, Global Healthcare Innovation Competitions, and road shows to China provide innovative companies who intend to enter China market with platforms for exposure to potential investors and partners.

Website:
https://en.mybiogate.com/
Mybiogate Inc.
Marketing Manager 

Lucky Chen United States

As China Focus conference organizer, MyBioGate is a premier cross-border healthcare consulting firm serving Biotech and Medtech clients, and the Chinese Pharma companies and investors. We offer marketing, strategy and execution support to help healthcare innovation to grow by taking advantage of China’s huge market potential. We help innovative companies with China-Landing services, and help them find reliable Chinese investors and partners. MyBioGate is committed to linking healthcare innovations in China and overseas. We share global healthcare innovation, entrepreneurship, investment trends, KOL opinions, important events and conferences, in-depth research and analysis, allowing Chinese medical and health companies and investors to gain insight into trends and seize investment opportunities. Our China Focus forums, Global Healthcare Innovation Competitions, and road shows to China provide innovative companies who intend to enter China market with platforms for exposure to potential investors and partners.

Website:
https://en.mybiogate.com/
Mybiogate Inc.

Youwen Dai United States

As China Focus conference organizer, MyBioGate is a premier cross-border healthcare consulting firm serving Biotech and Medtech clients, and the Chinese Pharma companies and investors. We offer marketing, strategy and execution support to help healthcare innovation to grow by taking advantage of China’s huge market potential. We help innovative companies with China-Landing services, and help them find reliable Chinese investors and partners. MyBioGate is committed to linking healthcare innovations in China and overseas. We share global healthcare innovation, entrepreneurship, investment trends, KOL opinions, important events and conferences, in-depth research and analysis, allowing Chinese medical and health companies and investors to gain insight into trends and seize investment opportunities. Our China Focus forums, Global Healthcare Innovation Competitions, and road shows to China provide innovative companies who intend to enter China market with platforms for exposure to potential investors and partners.

Website:
https://en.mybiogate.com/
Mybiogate Inc.
BD Director 

Paul DeRidder United States

Assist Consultation, Assistance, Service
• Identify Distribution Opportunities, Partners, Joint Ventures
• Guidance for Product Registration (SFDA), Regulatory Issues
• Intellectual Property Assessment
• Develop Successful Business Strategy
• Marketing/Analysis
• Manufacturing/Sourcing
• Investment Advisory
Website:
www.paulderiddermd.com
Company Size (Fulltime employees)
1-10
Year of foundation
2007
Looking for
Funding Status
self
Headquartner in China
No
Plan in China
Bring US based biomedical technology into China markets
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
BioValleyCHINA Ventures
President 
Functionality
Business Development

David Dill United States

We have, by a wide margin, the safest and most effective nocturia drug. Nocturia leads to over 10,000 deaths per day and costs the US economy $215B/year in lost worktime and lower productivity.
Website:
www.wellesleypharma.com
Company Size (Fulltime employees)
1-10
Year of foundation
2010
Looking for
Funding Status
Have raised $4.4 million of the $14.4 million needed to finish the clinical trial work needed for FDA approval.
Headquartner in China
No
Plan in China
To find a licensee that wants to provide a drug needed nightly by ten of millions of people in China alone and investors to fund our Phase 3 trial work.
Wellesley Pharmaceuticals, LLC
CEO & President 
Functionality
Management

Martin Duenas United States

OniX invest in companies in two ways: (1) Directly through it OniX Venture Fund and (2) Indirectly through its OniX hub members (includes pharma, VC, PE, family offices and private foundations)
Website:
https://www.onixhub.com/ | https://www.onixempirefund.com/
Company Size (Fulltime employees)
1-10
Year of foundation
2018
Looking for
Funding Status
Funded
Headquartner in China
No
Plan in China
TBD
OniX Hub
Founder/CEO 
Functionality
Management

Joseph Evans United States

Pleiogenix is a clinical-stage bio-pharmaceutical company that will develop safe and effective treatments for liver and other diseases with significant unmet medical needs. The initial diseases that Pleiogenix is targeting are acute alcoholic hepatitis (AAH), COVID-19, and non-alcoholic steatohepatitis (NASH) / Fibrosis, with additional diseases to follow. AAH is a deadly liver disease resulting in mortality in most patients within 6 months, in the absence of a liver transplant. NASH is a severe form of the chronic liver disease, non-alcoholic fatty liver disease (NAFLD). The AAH market is estimated to be $575 million by 2023, while the NASH market is estimated to be $35-40 billion by 2025. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; there have been ~34 million cases resulting in over 1,000,000 deaths (globally). There are no approved therapeutics that prevent or treat AAH, NASH, or COVID-19. Pleiogenix has identified a Phase 2A-ready drug candidate, PLG888, an orally available, pan-PPAR agonist (non-thiazolidinedione) that increases circulating adiponectin without eliciting body weight gain or edema. Adiponectin is a hormone possessing significant anti-inflammatory, anti-fibrotic and metabolic clinical benefits. In patients suffering from AAH, NASH, and COVID-19, inflammation is severely increased, and adiponectin is reduced in patients with NASH. Increased adiponectin is linked to decreased systemic inflammation, increased hepatic fat oxidation, decreased hepatic fibrosis, and amelioration of NASH. Thus, PLG888 has the potential to become the first prescription pharmaceutical for AAH, NASH / fibrosis, and/or COVID-19.
Website:
www.pleiogenix.com (under construction)
Company Size (Fulltime employees)
1-10
Year of foundation
2018
Looking for
Funding Status
Currently seeking $1 million Seed funding; detailed Use of Funds / Budget available
Headquartner in China
No
Plan in China
Plan to Enter China Market 1. PLG888 will be out-licensed to a commercialization partner to serve the China Market 2. China Market can be served by a specific licensing agreement, or as part of a broader licensing Asia-targeted agreement, that includes Japan, Korea, etc; this is open for discussion. 3. Overall Out-Licensing Strategy: restricted to specific indication and by specific world area (eg North America, EU, UK, Asia); some commercialization partners might prefer worldwide commercialization rights 4. Timing: AAH and COVID-19 and Other Indications: Out-License after Phase 3 / US registration; NASH / Fibrosis: Out-License after Phase 2B (due to high cost of Phase 3 development) 5. Revenue Model for Pleiogenix: Revenues will be derived from License and Milestone payments and Royalties on sales 6. EXIT STRATEGY: Pleiogenix will be attractive acquisition target based on future revenues derived from multiple out-licensing agreements within 3-5 years. AAH and COVID-19 and Other Indications: Out-License after Phase 3 / US registration NASH / Fibrosis: Out-License after Phase 2B (due to high cost of Phase 3 development) Revenue Model for Pleiogenix Revenues will be derived from License and Milestone payments and Royalties on sales EXIT STRATEGY: Pleiogenix will be attractive acquisition target based on future revenues derived from multiple out-licensing agreements
Pleiogenix Inc.
CEO & President 
Functionality
Management

Suzanne Ferguson United States

As China Focus conference organizer, MyBioGate is a premier cross-border healthcare consulting firm serving Biotech and Medtech clients, and the Chinese Pharma companies and investors. We offer marketing, strategy and execution support to help healthcare innovation to grow by taking advantage of China’s huge market potential. We help innovative companies with China-Landing services, and help them find reliable Chinese investors and partners. MyBioGate is committed to linking healthcare innovations in China and overseas. We share global healthcare innovation, entrepreneurship, investment trends, KOL opinions, important events and conferences, in-depth research and analysis, allowing Chinese medical and health companies and investors to gain insight into trends and seize investment opportunities. Our China Focus forums, Global Healthcare Innovation Competitions, and road shows to China provide innovative companies who intend to enter China market with platforms for exposure to potential investors and partners.

Website:
https://en.mybiogate.com/
Mybiogate Inc.
Operation Manager 

Zachary Fernandes United States

Mission Bio unlocks the ground truth of cancer through response, relapse, and remission with its Tapestri Platform, powered by single-cell multi-omics. As the first and only to analyze genotype and phenotype simultaneously in single cells, the Tapestri Platform can help unravel the inherent complexity of cancer. The technology discerns key biomarkers to stratify patients more precisely, signal treatment resistance as it begins, and predict relapse for better patient outcomes. Application areas include blood cancers, solid tumors, and genome editing validation.

Researchers at Memorial Sloan Kettering Cancer Center (MSK), MD Anderson Cancer Center (MDACC), and the University of California at San Francisco (UCSF) have leveraged the Tapestri Platform to support their research for characterizing clonal dynamics in a variety of cancers, identifying minimal residual disease (MRD), and monitoring treatment response and therapy resistance. The company’s award-winning technology is also leveraged by LabCorp and Agios to enable more efficient clinical trials.
Website:
www.missionbio.com
Year of foundation
2014
Looking for
Please specify your partnering goal
We are hoping to identify key commercial opportunities in academic, government, and industry centers. We have local representatives that assist with relationship management, procurement, services, etc.
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1: Name|Description|Indications|Stage|IP countries
Tapestri Platform|The Tapestri Platform is the only system capable of simultaneously providing both genotype and phenotype data from the same cell, across thousands of single cells. With DNA as a foundation, our proprietary two-step microfluidic workflow enables the simultaneous detection of analytes, including SNVs, CNVs, and proteins. Meet the complexity of cancer with true multi-omics analysis.|||
Biotech/Pharma Asset Stage
Mission Bio
Associate Director, Global Channel Development 
Functionality
Business Development

TED FUNG United States

Golden State Green World LLC, is a CBG Hemp Cultivator, located in Riverside County, California. Our team has ten years of extensive greenhouse design and a diverse growing experience. We apply our grow methodologies and eco-agricultural knowledge to supply the global market with high quality, contaminant-free, organic CBG enriched hemp products. Our vision is to become a global distributor of organic CBG infused products that will provided medical and therapeutically benefits to the end user.
Website:
www.gsgreenworld.com
Company Size (Fulltime employees)
1-10
Year of foundation
2014
Stock Market and Ticker/Symbol/Number
MGWFF
Looking for
Please specify your partnering goal
END PRODUCT TO CHINA
Funding Status
1ST TRANCHE
Now raising (In USD)
1 MILLION
Headquartner in China
No
Plan in China
Strategic development into extracting and manufacturing CBG isolate and oil medical, health supplement and cosmetics with our own brand name to China and Asia market
Biotech/Pharma Category
Golden State Green World
International Sales Manager 
Functionality
Sales and Marketing